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Teicoplanin is a glycopeptide antibiotic, produced by Actinoplanes teichomyceticus, active against Gram positive bacteria 
and recently introduced into clinical practice. It blocks cell wall biosynthesis by inhibiting peptidoglycan polymerization. 
The mechanism(s) of resistance of the producer strains of this class of antibiotics have not yet been characterized. We 
have constructed a genomic bank of A. teichomyceticus in Streptomyces lividans. A clone from this bank, pTR168, was 
able to confer esistance toteicoplanin on its sensitive host. The restriction map of plasmid pTR 168 and the hybridization 
pattern to A. teichomyceticus DNA were determined; we have also studied the mechanism of this resistance which seems 
correlated with a reduced binding of the antibiotic to the cell wall. 
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1. INTRODUCTION 
Antibiotic-producing microorganisms have 
developed a variety of mechanisms toresist o their 
own products; many of these mechanisms have 
been studied and fully characterized [1]. For the 
glycopeptide antibiotics no specific mechanisms of
resistance have been studied, so far, in producing 
strains. However clinical isolates resistant to these 
antibiotics are emerging [2] and some transferable 
resistances have already been described [3,4], 
although their mechanism of action has not yet 
been elucidated. 
We have investigated the resistance of Ac- 
tinoplanes teichomyceticus, producer of teico- 
planin [5], to its own product. 
Teicoplanin is a glycopeptide antibiotic, of the 
vancomycin class, recently introduced into clinical 
practice for treating serious Gram positive infec- 
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tions [6]. This antibiotic, like vancomycin, blocks 
cell wall biosynthesis by binding to amino-acyl-D- 
alanyl-D-alanine with consequent inhibition of 
peptidoglycan polymerization [7]. Teicoplanin is 
produced at the end of the logarithmic growth 
phase; at the same time the producing 
microorganism becomes resistant to the antibiotic. 
It was not known whether this apparent resistance 
was merely a reflection of the growth phase or in- 
volved genetic determinants specific to the pro- 
ducer strain. Against pathogenic bacteria, 
glycopeptide antibiotics, like other cell wall in- 
hibitors, are bactericidal only against actively 
growing cells [8]. 
2. MATERIALS AND METHODS 
2.1. Strains, plasmids and antibiotics 
Actinoplanes teichomyceticus (ATCC 31121) [9], Strep- 
tomyces lividans 66 (John Innes Collection 1326) [10] and the 
plasmid plJ702 (carrying the thiostrepton resistance gene) [10] 
were used. 
25 mg/l of thiostrepton (Sigma, St. Louis, MO, USA) were 
used for selecting clones resistant to this antibiotic; 
maintenance was on 50 mg/l. 20 mg/1 of teicoplanin were used 
for selection and maintenance of resistant cells. 
Vancomycin was from E. Lilly & Co. (Indianapolis, IN, 
USA); teicoplanin and A/40926 [11] were from Merrell Dow 
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Inc. (Cincinnati, OH). The M1C on S. lividans of the last 2 an- 
tibiotics is 3.2 mg/1. 
2.2. rDNA techniques 
Total DNA from A. teichomyceticus was extracted by the 
procedure of Hopwood et al. [10], except hat 5 mg/ml of 
lysozyme (Sigma) followed by 2 h of incubation, to protoplast 
the mycelium, were used. 
Restriction endonucleases were from Boehringer (Mannheim, 
FRG). Gibco/BRL Inc. (Gaithersburg, MD, USA) or New 
England Biolabs (Beverly, MA, USA). T4 DNA ligase and all 
other enzymes were from Boehringer. All enzymatic reactions 
were performed according to the supplier's instructions unless 
otherwise specified. 
Protocols for standard rDNA techniques were as described in 
the literature [10,12]. 
2.3. Teicoplanin binding assays 
2.3.1. Method A 
Streptomyces lividans, carrying plJ702 or the recombinant 
plasmid pTR168, conferring teicoplanin resistance, were grown 
at 30°C into late log phase. Two aliquots of each culture were 
centrifuged; the supernatants and the resuspended pellets were 
used to make the following mixtures: (A) S. lividans (plJ702) - 
its own supernatant; (B) S. lividans (plJ702) - supernatant 
from S. lividans (pTR168); (C) S. lividans (pTR168) - its own 
supernatant; (D) S. lividans (pTRI68) - supernatant from S. 
lividans (plJ702). To each mixture 10 mg/1 of 3H-labelled 
teicoplanin (37 kBq) were added followed by incubation at 
30°C for 20 min with agitation. Total input radioactivity was 
determined at the time of addition of the antibiotic. The in- 
cubated cultures were then centrifuged and the radioactivity of
the supernatants (i.e. not bound to the cells) determined. The 
pellets were washed with an equal volume of 0.9% NaCI and the 
radioactivity ofthe washing solution was determined along with 
that remaining bound to the cells. 
2.3.2. Method B 
The receptor-antibody binding assay (RASA) was performed 
according to Corti et al. [13]. Cultures of S. lividans harboring 
plJ702 or pTRI68 or uninoculated broth were incubated for 1 h 
at 30°C in the presence of 0.15 to 4.8 mg/1 of teicoplanin. After 
centrifugation the amount of teicoplanin remaining in the 
supernatants was determined. 
2.4. Other methods 
For high-performance liquid chromatography (HPLC) 
analysis, teicoplanin was recovered by filtration of broths 
through a D-alanyl-D-alanine agarose affinity column accor- 
ding to E. Riva et al. [14]. 
Sensitivity to other antibiotics was determined by depositing 
standard 6 mm antibiogram discs (BBL, Cockeysville, MD, 
USA) onto a layer of spores of the strain under investigation, 
and measuring the inhibition zones after 2 days of incubation 
at 28°C. 
3. RESULTS 
A.  teichomyceticus genomic DNA was part ia l ly  
digested with the restr ict ion endonuclease BamHI  
and size fract ionated.  The 2.5 to 10 kb fragments 
were l igated to Bgll I  l inearized and phosphatase-  
treated pl J702. This l igation mixture was used to 
t ransform S. l ividans 66 protoplasts;  about  11000 
t ransformants  containing recombinant  plasmids 
were obtained after selection with thiostrepton.  
Spore suspensions of  these t ransformants  were 
p lated at low density to select for te icoplanin 
resistance; one clone was selected for the abi l i ty to 
grow in the presence of  20 mg/ l  o f  the antibiot ic.  
The plasmid present in this clone was named 
pTR168. 
P lasmid pTR168 was extracted f rom the cells 
and util ised to retransform S. l ividans 66 pro-  
toplasts.  More than 95°70 of  the thiostrepton-  
resistant t ransformants  were also resistant to 
teicoplanin,  demonstrat ing that teicoplanin 
resistance was l inked to pTR168. 
The restr ict ion map of  the plasmid revealed an 
insert about  2600 base pairs long ( f ig. la) .  The 
restr ict ion map also shows the internal (SstI, KpnI)  
f ragment,  of  about  1500 base pairs,  used as a 
probe in a Southern blot hybr id izat ion with 
genomic DNA of  A.  teichometicus digested with 
var ious restr ict ion enzymes ( f ig. lb) .  The results 
obta ined are consistent with the hypothesis that the 
insert in pTR168 is present as a unique sequence in 
the A.  teicomyceticus genome. 
In table 1 we compare the sensitivity, to a 
number  of  antibiotics, o f  S. l ividans 66, harbor ing 
p l J702 or pTR168. As expected, the only dif- 
ference, between the two strains, was found for 
te icoplanin which did not inhibit pTR168 contain- 
ing cells; this strain also appeared to be slightly less 
sensitive to r i fampicin.  Both strains were also 
tested for their resistance to various glycopeptide 
antibiot ics:  vancomycin,  te icoplanin and A/40926. 
S. lividans seems to be intr insical ly resistant o 
vancomycin as it grew even on plates containing 
100 mg/ l  o f  this antibiot ic (data not shown). 
pTR168-contain ing cells grew with 100070 plating 
eff iciency in the presence of  100 mg/ l  o f  
te icoplanin or 50 mg/ l  o f  A/40926, while the 
strain harbor ing pI J702 was inhibited by 3.2 mg/ l  
o f  either antibiot ic.  These data suggest that the 
resistance conferred by pTR168 is specific for 
g lycopept ide antibiot ics but not for teicoplanin 
alone. 
No chemical modi f icat ion of  teicoplanin was 
detected by HPLC analysis of  supernatants of  
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Fig.1. (A) Restriction map of pTR168. At both ends of the insert two XholI sites were present, they arise from the joining of 
BgllI/BamHI sticky ends. No other XhoII sites are present in the insert. One SmaI site has not yet been precisely mapped; the two 
possible positions are indicated by symbols with stars. Recognition sites for the following restriction enzymes are not present: BamHI, 
BclI, Bg/II, ClaI, EcoRI, EcoRV, PstI, SphI, XhoI. Enzymes not mapped or not reported in the above list were not assayed. The 
thicker line between the inner Sstl and the KpnI recognition sites shows the fragment used as probe for the Southern hybridization. 
(B) Hybridization with A. teichomyceticus genomic DNA. Genomic DNA was subjected to restriction enzyme digestions, followed 
by electrophoretic separation of the restricted DNA, and then transferred onto a nylon membrane. The 32p-labelled probe was 
hybridized with genomic DNA from A. teichomyceticus at 65°C for 16 h. Excess probe was washed away with 15 mM NaCl and 
1.5 mM sodium citrate at the same temperature. Lane 1 contained the probe, as a positive control. The restricted genomic DNA was 
loaded in the other lanes, as follows: 2, KpnI-SstI; 3, BamHI; 4, PstI; 5, PvuII; 6, BglII. The lengths of the fragments revealed by 
the probe are indicated on the left; the smaller PvulI fragment was more visible in a longer exposure. 
resistant (pTR I68)  or  sensit ive (p l J702)  cultures 
after  up to 18 h o f  contact  with the ant ib iot ic  (data 
not  shown).  However ,  less te icop lan in  was 
recovered  f rom the culture o f  sensit ive cells; as i f  
these had bound more  ant ib iot ic  than the resistant 
ones.  Two possible mechan isms by which a cell 
cou ld  avo id  b ind ing this class o f  ant ib iot ics  are: (i) 
the product ion  o f  a molecu le  able to sequester  the 
ant ib iot ic  f rom the cul ture med ium;  (ii) the pro-  
duct ion  o f  a molecu le  able to mask  the b ind ing 
sites. 
We have studied the b ind ing o f  te icop lan in  to S. 
lividans carry ing either the parenta l  or  the recom-  
b inant  p lasmid.  
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Table 1 
Comparison ofthe activity of known antibiotics on S. lividans 
harboring the parental plasmid plJ702 or the recombinant 
plasmid pTR168 
Antibiotic mcg or (IU) a Inhibition zone (mm) 
per disc 
pIJ702 pTR 168 
Neomycin 30 13.5 12.5 
Paromomycin 30 15.5 14.5 
Kanamycin 30 22.5 21.5 
Gentamicin 10 12.5 12.5 
Tobramycin 10 14.0 13.5 
Amikacin 30 21.5 20.5 
Erythromycin 15 16.0 15.0 
Novobiocin 30 22.5 22.5 
Rifampicin 30 19.0 16.0 
Bacitracin (10) 21.0 21.0 
Teicoplanin 30 24.5 0 
a tu, international units 
Cultures of the two strains were prepared and 
cells reconstituted with homologous or 
heterologous supernatants as described in section 
2.3. As shown in table 2, the sensitive cells bound 
about half of the teicoplanin present in the 
medium. Regardless of the source of the superna- 
tant, very little antibiotic was removed by washing. 
The resistant cells, in either supernatant, did not 
bind significant amounts of antibiotic. 
We also evaluated the amount of free and bound 
teicoplanin by an immunological method (RASA). 
Again, sensitive cells bound the antibiotic more ef- 
ficiently than the resistant ones. For all the concen- 
trations tested, more than 85°7o f the teicoplanin 
remained in the supernatants of cells harboring 
Table 2 
Teicoplanin binding assay 
A B C D 
Mycelium: (plJ702) (plJ702) (pTR168) (pTRI68) 
Supernatant: (pIJ702) (pTR168)(pTR168) (pIJ702) 
Broth 46.5°70 42.7°70 85.0°70 83.1°7o 
Washing 5.5070 5.6°70 7.2070 6.7°70 
Cells 47.9°70 51.6o/o 7.6°70 10.0% 
Values are expressed asper cent of the total input radioactivity; 
the sum of each column is not exactly 100°70 because of the 
variability in the sampling and counting 
pTR168 while only 25o70 remained when cells bear- 
ing plJ702 were used. The differences in the 
binding values, obtained with plJ702-containing 
cells, between the two different methods might be 
due to the longer incubation time used in the 
RASA assay. 
4. DISCUSSION 
Antibiotic-producing microorganisms are com- 
monly resistant to their own products [1] and con- 
sequently have been used as sources for isolating 
antibiotic-resistance genes [15]. Various forms of 
self-defense have already been described; this is the 
first study of this type for glycopeptide producers. 
Our findings strongly suggest he presence of at 
least one gene involved in the resistance of A. 
teichomyceticus to its own product. Work is in 
progress to further analyse the structure of the 
DNA region present in pTR168 and to explore the 
possibility that more than one gene is involved in 
resistance of the producer strain. 
Recently, transferable resistance to these 
glycopeptide antibiotics was described in clinical 
isolates. Two different plasmids conferring 
resistance to glycopeptides were found in strains of 
E. faecium [4] and another transferable resistance 
has been associated with the appearance of a 
39 kDa protein in E. faecalis [3]. However the 
biochemical mechanisms of these resistances re- 
main unknown. Since the target of the antibiotic is 
in the cell wall, resistance due to an exclusion 
mechanism would seem unlikely [4,16]. Our data 
show that the resistance, induced by the presence 
of pTR168, is correlated with a reduced binding of 
teicoplanin to the cells. The protein(s) involved 
and possible changes in the cell wall structure are 
currently under investigation; the possible involve- 
ment of a S-layer [17] is also taken into considera- 
tion. Furthermore, it is interesting to note that the 
mechanism of resistance present in the pathogenic 
strains of E. faecium seems to be similar with that 
of the parental producer strain (Bernareggi, A. et 
al., unpublished). 
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